Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257750 · ClinicalTrials.gov registry record · Phase 1
Treatment of Corneal Neovascularization With Topical Pazopanib
A Phase 1 study, sponsored by Reza Dana, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01257750: Completed Phase 1 study, sponsored by Reza Dana, MD.
NCT01257750 is a Phase 1 study that has completed, run by Reza Dana, MD. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01257750, a Phase 1 study, has completed, sponsored by Reza Dana, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of a drug \[Pazopanib (Votrient)\] as a treatment for corneal neovascularization. The cornea is the clear, central portion of the eye and neovascularization means blood vessel growth. The cornea is typically avascular, or without blood vessels. Corneal neovascularization in the cornea and can put vision at risk. Numerous diseases of the cornea such as inflammation, ischemia (restriction of blood supply), infection, degeneration (or deterioration), trauma, or corneal stem cell deficiency can lead to corneal neovascularization. This major ocular complication can lead to corneal scarring, edema (swelling), lipid deposits, and inflammation that may significantly alter your vision. In addition, it worsens the outcome of potential future treatments, such as a corneal transplant. A corneal transplant is a treatment that many patients with severe corneal disease may ultimately need.
Primary Outcome
Heart rate through was measured throughout the study to assess subjects for systemic adverse events.
Interventions
- DRUG Pazopanib (5mg/ml)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
What the finished NCT01257750 record still lists
NCT01257750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Pazopanib (5mg/ml) is the first listed.
NCT01257750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01257750 about?
NCT01257750 is a clinical study titled "Treatment of Corneal Neovascularization With Topical Pazopanib". The purpose of this study is to determine the safety and efficacy of a drug \[Pazopanib (Votrient)\] as a treatment for corneal neovascularization. The cornea is the clear, central portion of the eye and neovascularization means blood vessel growth. The cornea is typically avascular, or without bloo...
What is the current status of trial NCT01257750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01257750?
The interventions under investigation include: Pazopanib (5mg/ml) (DRUG).
Who is sponsoring clinical trial NCT01257750?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01257750's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia